External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy
European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8514-8518
DOI: 10.1007/s00259-026-08169-7 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 08.09.2026. Verfasst von Thomas Büttner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Pediatric Urology, University Hospital Bonn, Venusberg-Campus 1, Bonn, 53127, Germany. Thomas.Buettner@ukbonn.de. Hauptthemen laut MEDLINE: Dipeptides, Heterocyclic Compounds, 1-Ring, Prostatic Neoplasms, Castration-Resistant, Lutetium. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Bonn.
Abstract (Originalsprache)
Purpose [ 177 Lu]Lu-PSMA-617 is a standard-of-care therapy for metastatic castration-resistant prostate cancer (mCRPC). Given the heterogeneous clinical responses, accessible prognostic tools are needed. We recently demonstrated that the Bellmunt Risk Score (BRS)—comprising ECOG performance status >0, hemoglobin
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology and Pediatric Urology, University Hospital Bonn, Venusberg-Campus 1, Bonn, 53127, Germany. Thomas.Buettner@ukbonn.de.
- Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
- Martini-Klinik Prostate Cancer Center, University Hospital Hamburg- Eppendorf, Hamburg, Germany.
- Department of Urology and Pediatric Urology, University Hospital Bonn, Venusberg-Campus 1, Bonn, 53127, Germany.
- Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
- Department of Nuclear Medicine, Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Frankfurt am Main, Germany.
Förderung
- Universitätsklinikum Bonn
Zitieren
APA
Büttner, T., Wenzel, M., Mandel, P., Schmitt, P., Hoffmann, C., Marinova, M., Essler, M., Chun, F. K. H., Ritter, M., Groener, D., & Krausewitz, P. (2026). External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8514-8518. https://doi.org/10.1007/s00259-026-08169-7
Vancouver
Büttner T, Wenzel M, Mandel P, Schmitt P, Hoffmann C, Marinova M, et al. External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8514-8518. doi:10.1007/s00259-026-08169-7
BibTeX
@article{Bttner2026,
author = {Büttner, Thomas and Wenzel, Mike and Mandel, Philipp and Schmitt, Paul and Hoffmann, Christian and Marinova, Milka and Essler, Markus and Chun, Felix K H and Ritter, Manuel and Groener, Daniel and Krausewitz, Philipp},
title = {External validation of the bellmunt risk score for survival prediction in mCRPC patients undergoing [177Lu]Lu-PSMA-617 therapy},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
volume = {53},
number = {13},
pages = {8514--8518},
doi = {10.1007/s00259-026-08169-7}
}
EUVIMED